Payment overview · 2025
General Payments
$153.11
8 reported records · 4 companies
Healthcare provider profile · identity verified
Keith R Cook, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1396740957
Verified facts
What the public records show
CMS Open Payments records show Keith R Cook, MD received $153.11 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.48 | 59.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.61 | 23.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.19 | 11.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.83 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.11 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.11 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 469 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 110 |
| Omeprazole | Omeprazole | 363 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 99 |
| Lisinopril | Lisinopril | 333 | 92 |
| Alprazolam | Alprazolam | 268 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 68 |
| Losartan Potassium | Losartan Potassium | 212 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 64 |
| Meloxicam | Meloxicam | 188 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 57 |
| Gabapentin | Gabapentin | 180 | 40 |
| Metformin Hcl Er | Metformin Hcl | 177 | 56 |
| Sertraline Hcl | Sertraline Hcl | 177 | 45 |
| Potassium Chloride | Potassium Chloride | 168 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 46 |
| Glimepiride | Glimepiride | 152 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 39 |
| Furosemide | Furosemide | 147 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 38 |
| Eliquis | Apixaban | 139 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 139 | 43 |
| Xarelto | Rivaroxaban | 139 | 27 |
| Trazodone Hcl | Trazodone Hcl | 130 | 32 |
| Tramadol Hcl | Tramadol Hcl | 129 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 35 |
| Carvedilol | Carvedilol | 120 | 33 |
| Simvastatin | Simvastatin | 120 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 29 |
| Famotidine | Famotidine | 101 | 31 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 99 | 27 |
| Lorazepam | Lorazepam | 99 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 29 |
| Celecoxib | Celecoxib | 95 | 29 |
| Metformin Hcl | Metformin Hcl | 92 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 85 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 22 |
| Allopurinol | Allopurinol | 83 | 23 |
| Diazepam | Diazepam | 83 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 14 |
| Atenolol | Atenolol | 80 | 26 |
| Fluconazole | Fluconazole | 75 | 31 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | suppressed |
| Clonazepam | Clonazepam | 69 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 61 | 16 |
| Methylprednisolone | Methylprednisolone | 60 | 42 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Warfarin Sodium | Warfarin Sodium | 57 | 12 |
| Finasteride | Finasteride | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 18 |
| Midodrine Hcl | Midodrine Hcl | 56 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 15 |
| Montelukast Sodium | Montelukast Sodium | 52 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 12 |
| Mirtazapine | Mirtazapine | 44 | 12 |
| Colchicine | Colchicine | 42 | 16 |
| Spironolactone | Spironolactone | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 19 |
| Digoxin | Digoxin | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 14 |
| Prednisone | Prednisone | 37 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Methimazole | Methimazole | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Estradiol | Estradiol | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.11 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, JARDIANCE, Ozempic, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error